Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
necitumumab + osimertinib
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of necitumumab, an IgG1 monoclonal antibody EGFR antagonist, and osimertinib, an EGFR tyrosine kinase inhibitor. This combination targets EGFR through complementary mechanisms - necitumumab binds to the extracellular domain of EGFR preventing ligand binding, while osimertinib blocks enzymes needed for cell growth by targeting EGFR mutations. The combination has been investigated for treatment of EGFR-mutant non-small cell lung cancer after progression on previous EGFR tyrosine kinase inhibitors.
02
Targets
Beyond the preview
Go deeper on necitumumab + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on necitumumab + osimertinib.